Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Harjai, K. J.    Related Articles in PubMed    PubMed Citation    PubMed

REVIEW

Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen

Kishore J. Harjai, MBBS

7 September 1999 | Volume 131 Issue 5 | Pages 376-386

The 1996 Bethesda Conference acknowledged left ventricular hypertrophy, hyperhomocysteinemia, lipoprotein(a) excess, hypertriglyceridemia, oxidative stress, and hyperfibrinogenemia as possible new cardiac risk factors. This review summarizes the current literature that supports these conditions as cardiac risk factors. Left ventricular hypertrophy is an independent risk factor for vascular disease. Improvement or progression of left ventricular hypertrophy influences subsequent cardiovascular complications. Clinical trials are under way to assess the potential benefit of decreasing homocysteine levels. The role of lipoprotein(a) excess in vascular disease is controversial. The atherogenic potential of lipoprotein(a) seems to be neutralized by effective reduction of low-density lipoprotein cholesterol levels. Increasing evidence supports an independent role of hypertriglyceridemia in cardiovascular disease and a possible clinical benefit from decreasing triglyceride levels. Among antioxidant micronutrients, supplementation with vitamin E has been shown to be beneficial in primary and secondary prevention studies. Data supporting the use of other antioxidants are much weaker. Preliminary evidence suggests that reducing fibrinogen levels in patients with high baseline levels and coronary disease may be beneficial. Despite the potential relation between new risk factors and cardiovascular disease, routine clinical application of these conditions as cardiovascular risk factors would be premature. Evidence is needed that these conditions extend prognostic ability beyond conventional risk factors and that modification of these conditions can reduce the risk for cardiovascular events.

Author and Article Information

From the Ochsner Clinic, New Orleans, Louisiana.

Current Author Address: Kishore J. Harjai, MBBS, Department of Cardiology, Ochsner Clinic, 1514 Jefferson Highway, New Orleans, LA 70121; e-mail, kharjai{at}ochsner.org.

Related articles in Annals:

Letters
Potential New Cardiovascular Risk Factors
Bruce L. Rollman, Peter F. Counihan, AND Charles F. Reynolds

Annals 2000 132: 761. [Full Text]  

This article has been cited by other articles:

				M. May, J. A C Sterne, M. Shipley, E. Brunner, R. d'Agostino, P. Whincup, Y. Ben-Shlomo, A. Carr, B. Ledergerber, J. D Lundgren, et al. A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men Int. J. Epidemiol., December 1, 2007; 36(6): 1309 - 1318. [Abstract] [Full Text] [PDF]

				E. S. Ganotakis, I. F. Gazi, J. A. Papadakis, I. A. Jagroop, D. R. Nair, and D. P. Mikhailidis The Relationship Between Circulating Fibrinogen and Lipoprotein (a) Levels in Patients With Primary Dyslipidemia Clinical and Applied Thrombosis/Hemostasis, January 1, 2007; 13(1): 35 - 42. [Abstract] [PDF]

				S. Mora, N. Rifai, J. E. Buring, and P. M Ridker Additive Value of Immunoassay-Measured Fibrinogen and High-Sensitivity C-Reactive Protein Levels for Predicting Incident Cardiovascular Events Circulation, August 1, 2006; 114(5): 381 - 387. [Abstract] [Full Text] [PDF]

				M. D. Faulx, P. Ernsberger, D. Vatner, R. D. Hoffman, W. Lewis, R. Strachan, and B. D. Hoit Strain-dependent {beta}-adrenergic receptor function influences myocardial responses to isoproterenol stimulation in mice Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H30 - H36. [Abstract] [Full Text] [PDF]

				T. Zhang and J. H. Brown Role of Ca2+/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure Cardiovasc Res, August 15, 2004; 63(3): 476 - 486. [Abstract] [Full Text] [PDF]

				F. Orio Jr., S. Palomba, L. Spinelli, T. Cascella, L. Tauchmanova, F. Zullo, G. Lombardi, and A. Colao The Cardiovascular Risk of Young Women with Polycystic Ovary Syndrome: An Observational, Analytical, Prospective Case-Control Study J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3696 - 3701. [Abstract] [Full Text] [PDF]

				A. Colao, D. Ferone, P. Marzullo, and G. Lombardi Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management Endocr. Rev., February 1, 2004; 25(1): 102 - 152. [Abstract] [Full Text] [PDF]

				L. E. Eberly, J. Stamler, and J. D. Neaton Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease Arch Intern Med, May 12, 2003; 163(9): 1077 - 1083. [Abstract] [Full Text] [PDF]

				M.-o Date, T. Morita, N. Yamashita, K. Nishida, O. Yamaguchi, Y. Higuchi, S. Hirotani, Y. Matsumura, M. Hori, M. Tada, et al. The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model J. Am. Coll. Cardiol., March 6, 2002; 39(5): 907 - 912. [Abstract] [Full Text] [PDF]

				D. B. Sacks, D. E. Bruns, D. E. Goldstein, N. K. Maclaren, J. M. McDonald, and M. Parrott Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus Clin. Chem., March 1, 2002; 48(3): 436 - 472. [Abstract] [Full Text] [PDF]

				P. B. Gorelick Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy: An Invited Review Stroke, March 1, 2002; 33(3): 862 - 875. [Abstract] [Full Text] [PDF]

				R. Padwal, S. E Straus, and F. A McAlister Evidence based management of hypertension: Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review BMJ, April 21, 2001; 322(7292): 977 - 980. [Full Text]

				T. Kwok, J. Woo, S. Ho, and A. Sham Vegetarianism and Ischemic Heart Disease in Older Chinese Women J. Am. Coll. Nutr., October 1, 2000; 19(5): 622 - 627. [Abstract] [Full Text] [PDF]

				C.G. Isles and J.R. Paterson Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy QJM, September 1, 2000; 93(9): 567 - 574. [Abstract] [Full Text] [PDF]

				A. Oberman Hypertriglyceridemia and Coronary Heart Disease J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2098 - 2105. [Full Text]

				B. L. Rollman, P. F. Counihan, and C. F. Reynolds Potential New Cardiovascular Risk Factors Ann Intern Med, May 2, 2000; 132(9): 761 - 761. [Full Text] [PDF]

				T. Zhang, E. N. Johnson, Y. Gu, M. R. Morissette, V. P. Sah, M. S. Gigena, D. D. Belke, W. H. Dillmann, T. B. Rogers, H. Schulman, et al. The Cardiac-specific Nuclear delta B Isoform of Ca2+/Calmodulin-dependent Protein Kinase II Induces Hypertrophy and Dilated Cardiomyopathy Associated with Increased Protein Phosphatase 2A Activity J. Biol. Chem., January 4, 2002; 277(2): 1261 - 1267. [Abstract] [Full Text] [PDF]